Vancouver
A more recent version of this article appeared on November 1, 2007

Published online before print August 14, 2007
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow Erratum (v83,p1068)
Right arrow All Versions of this Article:
jlb.0407255v1
82/5/1062    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lubick, K.
Right arrow Articles by Jutila, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lubick, K.
Right arrow Articles by Jutila, M.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0407255

Received for publication April 26, 2007.
Revised June 27, 2007.
Accepted for publication July 18, 2007.

Article

Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists

Kirk Lubick , Miranda Radke , and Mark Jutila @

Veterinary Molecular Biology, Montana State University, Bozeman, Montana, USA

@ To whom correspondence should be addressed. E-mail: uvsmj{at}montana.edu.


arrow
Abstract

Innate immune cell stimulation represents a complementary approach to vaccines and antimicrobial drugs to counter infectious disease. We have used assays of macrophage activation and in vitro and in vivo phase II Coxiella burnetii infection models to compare and contrast the activity of a novel innate immune cell agonist, securinine, with known TLR agonists. As expected, TLR agonists, such as LPS (TLR4) and fibroblast-stimulating lipopeptide-1 (FSL-1; TLR2), induced macrophage activation and increased macrophage killing of phase II C. burnetii in vitro. FSL-1 also induced accelerated killing of C. burnetii in vivo. Securinine, a {gamma}-aminobutyric acid type A receptor antagonist, was found to induce TLR-independent macrophage activation in vitro, leading to IL-8 secretion, L-selectin down-regulation, and CD11b and MHC Class II antigen up-regulation. As seen with the TLR agonists, securinine also induced accelerated macrophage killing of C. burnetii in vitro and in vivo. In summary, as predicted by the literature, TLR agonists enhance macrophage killing of phase II C. burnetii in vitro, and at least for TLR2 agonists, this activity occurs in vivo as well. Securinine represents a novel macrophage agonist, which has similar effects as TLR agonists in this model yet apparently, does not act through known TLRs. Securinine has minimal toxicity in vivo, suggesting it or structurally similar compounds may represent novel, therapeutic adjuvants, which increase resistance to intracellular pathogens.

Key Words: adjuvant therapy • innate immunity • antimicrobial drugs • infectious disease • leukocyte




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. J. Thompson, S. J. Dunstan, C. Dolecek, T. Perkins, D. House, G. Dougan, N. T. Hue, T. T. Phi La, D. C. Du, L. T. Phuong, et al.
Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi
PNAS, December 29, 2009; 106(52): 22433 - 22438.
[Abstract] [Full Text] [PDF]